LabTech launches MicroStreak in US
Wednesday, 11 June, 2008
Adelaide-based diagnostics company LabTech Systems (ASX: LBT) has launched its MicroStreak technology in the US.
The company held a launch for the product, which has been named PREVI Isola by licensees bioMerieux, at the American Society of Microbiology meeting held in Boston this week.
MicroStreak is a new method of microbiology processing, automating the streaking of agar plates to test samples. The technology was already launched in Europe in April.
LabTech has earned $4.9 million in licence fees to date.
For a full report on the MicroStreak, see the July/August edition of Australian Life Scientist.
Organoid platform enables closer study of bat-borne viruses
Reconstructing bat organ physiology in the lab lets scientists explore how zoonotic viruses work...
Global study finds 250 genes linked to OCD
Researchers say they have found the genes linked to obsessive compulsive disorder (OCD), after...
TGA approves therapy for paediatric growth hormone deficiency
The TGA has approved SKYTROFA as a treatment for growth failure in children and adolescents aged...
